Industry talk: Introduction of Boehringer Ingelheim and Research Beyond Borders
Date : 23 April, 2018 (Monday)
Time : 9:30 – 10:15 am
Venue : Mrs Chen Yang Foo Oi Telemedicine Centre, 2/F, Room A2-08, William M.W. Mong Block, Faculty of Medicine
Speaker : Dr Henri DOODS, Global Head, Research Beyond Borders of Boehringer Ingelheim
About the company :
Boehringer Ingelheim (BI) is a global, research-driven pharmaceutical company embracing many cultures and diverse societies. Innovative medicines for people and animals have for more than 130 years been what BI stands for. BI is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas: Human pharmaceuticals, Animal health and Biopharmaceutical contract manufacturing. In Human pharmaceuticals, core therapeutic areas are CardioMetabolic diseases, Central Nervous System diseases, Immunology and Respiratory diseases, Oncology and Cancer Immunology.
Research Beyond Borders (RBB) is a function under the Innovation Unit of BI’s Human Pharmaceuticals which explores emerging science and technologies, for and beyond BI’s core therapeutic areas, to create new opportunities and capabilities for drug discovery and development. RBB will help facilitate BI’s timely and efficient entry into new research fields to develop solutions in areas of high unmet medical need for the benefit of patients. RBB integrates both internal and external insights and opportunities, and explores new models for collaboration, to bring together the talents and capabilities of our scientists with the strengths of scientists around the world. Partnering interests include Regenerative medicine, Gene therapy, Tumor microbiome, Hearing disorders, Cachexia and Multi-drug resistant infectious diseases.
About the Speaker :
Henri DOODS received his PhD in Pharmacology at the University of Amsterdam. He joined Boehringer Ingelheim in 1987 and covered different positions within Cardiovascular, Pain, Obesity, Central Nervous System and Respiratory research. Currently, Henri heads the Global Department of Research Beyond Borders with teams in Europe, USA and Asia, responsible to capture emerging science/new indications and novel technologies/modalities. He co-authors more than 135 publications and was involved in progressing of more than 15 compounds into development.
Boehringer Ingelheim (BI) is looking for collaborations with researchers in HKU. This talk will introduce the background, research focuses and collaboration modes of BI.
For HKU Staff and Students : https://hkuems1.hku.hk/hkuems/ec_regform.aspx?ueid=55849
For Public : https://hkuems1.hku.hk/hkuems/ec_regform.aspx?guest=Y&ueid=55849